ESPR — Esperion Therapeutics Share News
0.000.00%
Last trade - 00:00- $822.04m
- $1.21bn
- $403.14m
Esperion Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Esperion Announces $210 Mln Convertible Debt Financing
Brief: Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel
Brief: Esperion Announces New Drug Submissions in Canada for NEXLETOL and NEXLIZET Treatments to Reduce LDL-C and Cardiovascular Risk
Brief: Otsuka Submits New Drug Application In Japan For Bempedoic Acid In The Treatment Of Hypercholesterolemia
Esperion Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Esperion Therapeutics Q3 Basic EPS USD -0.15
Brief: Esperion Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Esperion Secures Additional Commercial And Medicare Formulary Coverage For Nexletol(Bempedoic Acid) And Nexlizet(Bempedoic Acid And Ezetimibe)
U.S. RESEARCH ROUNDUP- Apollo, Blackstone, Hershey
Brief: Esperion Therapeutics Q2 Basic EPS USD -0.33
Esperion Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Esperion Therapeutics Inc European Commission Approved Label Update Of Both Nilemdo And Nustendi
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Micron, Target
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Dyne Therapeutics, AZZ
U.S. STOCKS ON THE MOVE-Nvidia, Johnson Controls, Paramount Global
U.S. STOCKS ON THE MOVE-JPMorgan, Wix.com, EHang
Esperion rises as cholesterol drug succeeds in late-stage study in Japan